摘要
目的观察降钙素联合氯化89鍶治疗恶性肿瘤骨转移痛的疗效,判断降钙素在治疗中的作用。方法 73名恶性肿瘤骨转移病例分为,联合组29例患者,用氯化^(89)鍶(3-4mci iv)+降钙素(100IU喷鼻1次/天);氯化^(89)鍶治疗组25例患者,用氯化^(89)鍶(3-4mci iv)和对照组19例患者,不同意锶治疗的肿瘤骨转移病人(其它方法治疗骨痛),观察镇痛总有效率并以火焰原子吸收法测定全血鍶含量,随诊12个月,2例死亡退出观察。结果联合治疗组疗效高峰出现在第一个月,总有效率96.4%(27/28);绿化锶组疗效高峰出现在第一个月,总有效率83.33%(20/24),两治疗组比较差异显著(P<0.01);联合治疗组血锶水35.5μg/L,明显低于氯化^(89)鍶组和对照组(P<0.05)。氯化锶组血锶水平39.8μg/L,与对照组血鍶含量无显著性差异(P>0.05)。结论降钙素联合氯化^(89)鍶镇痛效果显著好于氯化锶组(P<0.01);降钙素促进骨转移灶对^(89)鍶吸收,降钙素可以作为氯化^(89)鍶的增效剂。
Objective To observe the effect of salmon calcitonin on concentration of blood 89 Sr and efficacy of treatment combined with ^89SrCl2 in blood of cancer patients with bone metastases. Methods There were 73 cases cancer patients with bone metastases selected from October 2013 to October 2014.29 cases were treated with ^89SrCl2 （4mci iv） combined with salmon calcitonin; 25 cases were treated with ^89SrCl2 and the 19 with other therapy. The total response rate and the pain level was estimated, the ^89Sr concentrations in blood were measured by Flame atomic absorption spec trophotometer. Two patients withdrawn due to death and all patients were followed up one year. Results The 28 patients were treated with ^89SrCl2 （4mci iv） combined with salmon calcitonin, the pain levels were relieved in all patients except one （96.4%）^89SrCl2 group were 83.33% （20/24）. the ^89Sr concentrations in blood of combined group were lower than ^89SrC;2 group or control group;There were no difference in concentration of ^89Sr in blood between ^89SrCl2 group and control group（P〉0.05）after statistical analysis. Conclusion Salmon calcitonin can enhance absorbtion of ^89Sr the foci and synergetic role with ^89SrCl2 efficacy of cancer bone metastase.
出处
《中国实验诊断学》
2016年第6期941-943,共3页
Chinese Journal of Laboratory Diagnosis
